• 1. Domino Rh-catalyzed hydroformylation–double cyclization of o-amino cinnamyl derivatives: applications to the formal total syntheses of physostigmine and physovenine
  Wen-Hua Chiou,Chien-Lun Kao,Jui-Chi Tsai,Yun-Man Chang Chem. Commun. 2013 49 8232
• 2. Catalytic asymmetric preparation of pyrroloindolines: strategies and applications to total synthesis
  Guang-Jian Mei,Wai Lean Koay,Chuan Xiang Alvin Tan,Yixin Lu Chem. Soc. Rev. 2021 50 5985
• 3. Natural products as a source of Alzheimer's drug leads
  Philip Williams,Analia Sorribas,Melanie-Jayne R. Howes Nat. Prod. Rep. 2011 28 48
• 4. Recent advances in dearomatization of heteroaromatic compounds
  Qiuping Ding,Xiaoli Zhou,Renhua Fan Org. Biomol. Chem. 2014 12 4807
• 5. Synthesis of pyrroloindolines and furoindolines via cascade dearomatization of indole derivatives with carbenium ion
  Chuan Liu,Qin Yin,Li-Xin Dai,Shu-Li You Chem. Commun. 2015 51 5971

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Indoles and derivatives Pyrroloindoles

Phenserine (CAS No. 101246-66-6): A Comprehensive Overview of Its Applications and Recent Research Findings

Phenserine, with the chemical name CAS No. 101246-66-6, is a compound that has garnered significant attention in the field of pharmaceutical research and development. This introduction aims to provide a detailed exploration of Phenserine, its chemical properties, mechanisms of action, and the most recent research findings that highlight its potential applications in medicine and biotechnology.

The compound Phenserine belongs to a class of molecules known for their interaction with biological targets, particularly enzymes and receptors involved in critical cellular processes. Its molecular structure, characterized by specific functional groups, contributes to its unique pharmacological profile. The chemical formula and structural elucidation of Phenserine have been thoroughly studied, providing insights into its binding affinity and metabolic pathways.

In recent years, Phenserine has been extensively investigated for its potential therapeutic effects. One of the most promising areas of research is its role in neurodegenerative diseases. Studies have demonstrated that Phenserine can modulate the activity of acetylcholinesterase, an enzyme crucial for maintaining acetylcholine levels in the brain. This modulation has shown promise in alleviating symptoms associated with conditions such as Alzheimer's disease and other cognitive impairments.

The mechanism of action of Phenserine involves not only its interaction with acetylcholinesterase but also its ability to influence other key neurotransmitter systems. Research has indicated that Phenserine can enhance cholinergic neurotransmission, which is essential for cognitive functions like memory and learning. Furthermore, it has been observed to have neuroprotective effects by mitigating oxidative stress and inflammation, which are hallmark features of neurodegenerative disorders.

Epidemiological studies have also highlighted the potential benefits of Phenserine in aging populations. The compound's ability to cross the blood-brain barrier efficiently makes it a candidate for oral administration, which is a significant advantage in clinical settings. Preclinical trials have shown encouraging results regarding its safety profile and tolerability, suggesting that it could be a viable therapeutic option for elderly patients experiencing cognitive decline.

The synthesis and characterization of Phenserine have been refined through advanced chemical methodologies. Researchers have developed efficient synthetic routes that ensure high purity and yield, making it feasible for large-scale production. Analytical techniques such as nuclear magnetic resonance (NMR) spectroscopy, mass spectrometry (MS), and X-ray crystallography have been employed to confirm the structural integrity of the compound.

In addition to its neuropharmacological applications, Phenserine has shown promise in other therapeutic areas. Preliminary studies have explored its potential role in modulating immune responses, making it a candidate for immunomodulatory therapies. The compound's ability to interact with immune cells and regulate cytokine production has sparked interest in its use for treating inflammatory diseases.

The pharmacokinetic properties of Phenserine, including its absorption, distribution, metabolism, and excretion (ADME), have been thoroughly evaluated. These studies have provided valuable insights into how the body processes the compound and how long it remains active within the system. This information is crucial for optimizing dosing regimens and minimizing potential side effects.

The regulatory landscape for Phenserine is evolving as more research emerges. Regulatory agencies are closely monitoring the progress of clinical trials to assess its efficacy and safety for human use. The path towards regulatory approval will depend on the outcomes of ongoing studies and whether they meet stringent criteria set by health authorities.

The future directions of research on Phenserine are multifaceted. Scientists are exploring new derivatives that could enhance its therapeutic potential while reducing side effects. Additionally, investigating its interactions with other biological targets may uncover novel applications beyond its current scope.

In conclusion, Phenserine (CAS No. 101246-66-6) represents a significant advancement in pharmaceutical research with diverse applications in medicine. Its ability to modulate key neurotransmitter systems and exhibit neuroprotective properties makes it a promising candidate for treating neurodegenerative diseases. As ongoing research continues to uncover new insights into its mechanisms of action and therapeutic benefits, Phenserine is poised to play a vital role in addressing some of the most challenging health issues faced by humanity today.

• 57-47-6(Physostigmine)
• 103877-07-2((-)-n-methylphysostigmine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)